Premium
Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer‐bearing dogs
Author(s) -
Allstadt Frazier S.,
McKemie D. S.,
Guerrero T. A.,
LaChapelle H.,
Skorupski K. A.,
Kass P. H.,
Rodriguez C. O.
Publication year - 2014
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2012.00322.x
Subject(s) - rosiglitazone , carboplatin , medicine , toxicity , agonist , pharmacology , endocrinology , chemotherapy , receptor , cisplatin
Rosiglitazone is an FDA‐approved peroxisome proliferator‐activated receptor gamma (PPARγ) agonist and antidiabetic agent in humans that has been investigated for its ability to reduce tumor cell growth. The purpose of this study was to determine the maximally tolerated dose, peak plasma concentrations and side effect profile of oral rosiglitazone when combined with carboplatin in dogs with cancer. Rosiglitazone was administered at 6 and 8 mg/m 2 to seven dogs. Carboplatin was administered at 240–300 mg/m 2 in combination with rosiglitazone. For toxicity evaluation, the toxicity data for the seven dogs in this study were combined with the toxicity data from three dogs previously reported in a methodology study. Peak plasma rosiglitazone concentrations varied with dose. The dose‐limiting toxicity was hepatic at a dose of 8 mg/m 2 . Three dogs had mild to moderate alanine aminotransferase elevations but no changes in total bilirubin, alkaline phosphatase, blood glucose or γ‐glutamyltranspeptidase values were noted.